ATE357922T1 - Heilung und vorbeugung von durch nf-kappab verursachten erkrankungen - Google Patents

Heilung und vorbeugung von durch nf-kappab verursachten erkrankungen

Info

Publication number
ATE357922T1
ATE357922T1 AT96913716T AT96913716T ATE357922T1 AT E357922 T1 ATE357922 T1 AT E357922T1 AT 96913716 T AT96913716 T AT 96913716T AT 96913716 T AT96913716 T AT 96913716T AT E357922 T1 ATE357922 T1 AT E357922T1
Authority
AT
Austria
Prior art keywords
diseases caused
kappab
cure
diseases
prevent diseases
Prior art date
Application number
AT96913716T
Other languages
English (en)
Inventor
Ryuichi Morishita
Toshio Ogihara
Toshiko Sugimoto
Kazuhiro Maeda
Ikuo Kawamura
Toshiyuki Chiba
Original Assignee
Anges Mg Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anges Mg Inc filed Critical Anges Mg Inc
Application granted granted Critical
Publication of ATE357922T1 publication Critical patent/ATE357922T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT96913716T 1995-05-12 1996-05-10 Heilung und vorbeugung von durch nf-kappab verursachten erkrankungen ATE357922T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP11499095 1995-05-12
JP28550495 1995-11-02

Publications (1)

Publication Number Publication Date
ATE357922T1 true ATE357922T1 (de) 2007-04-15

Family

ID=26453615

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96913716T ATE357922T1 (de) 1995-05-12 1996-05-10 Heilung und vorbeugung von durch nf-kappab verursachten erkrankungen

Country Status (9)

Country Link
US (4) US6262033B1 (de)
EP (1) EP0824918B1 (de)
JP (1) JP3474879B2 (de)
AT (1) ATE357922T1 (de)
DE (1) DE69636997T2 (de)
DK (1) DK0824918T3 (de)
ES (1) ES2285712T3 (de)
PT (1) PT824918E (de)
WO (1) WO1996035430A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT732929E (pt) * 1993-10-29 2008-08-26 Brigham & Womens Hospital Utilização terapêutica de ''engodos'' de elementos cis in vivo
DE69636997T2 (de) * 1995-05-12 2007-07-12 Anges MG Inc., Ibaraki HEILUNG UND VORBEUGUNG VON DURCH NF-kappaB VERURSACHTEN ERKRANKUNGEN
DE69814618T2 (de) 1997-02-15 2004-03-25 Millenium Pharmaceuticals, Inc., Cambridge Behandlung von infarkten durch inhibierung von nf-kappab
US6586661B1 (en) * 1997-06-12 2003-07-01 North Carolina State University Regulation of quinolate phosphoribosyl transferase expression by transformation with a tobacco quinolate phosphoribosyl transferase nucleic acid
JP4215219B2 (ja) 1997-07-04 2009-01-28 アンジェスＭｇ株式会社 脳保護剤
WO2000005234A1 (fr) * 1998-07-22 2000-02-03 Suntory Limited INHIBITEURS DE NF-λB CONTENANT DES DERIVES D'INDANE EN TANT QU'INGREDIENT ACTIF
AU5329599A (en) 1998-07-30 2000-02-21 University Of South Florida Method for the modulation of function of transcription factors
DE19926216A1 (de) * 1999-06-09 2001-02-22 Metallgesellschaft Ag Verfahren zur Herstellung von Bariumsulfat, Bariumsulfat und Verwendung des Bariumsulfats
HUP0104841A3 (en) * 1999-09-17 2002-07-29 Daiichi Suntory Pharma Co Ltd Medicaments containing benzoquinone- or condensed pyrimidine derivatives as active ingredient for treating of myocarditis, dilated cardiomyopathy and cardiac insufficiency
US7192771B2 (en) * 2000-08-30 2007-03-20 North Carolina State University Plant promoter sequence
JP2002065278A (ja) * 2000-08-31 2002-03-05 Anges Mg Inc Ｈｖｊの融合タンパク質を含有する遺伝子移入ビヒクル
CN1258593C (zh) * 2000-11-07 2006-06-07 北卡罗莱纳州立大学 腐胺－n－甲基转移酶启动子
WO2002069995A2 (en) * 2001-02-16 2002-09-12 Medical College Of Georgia Research Institute, Inc. Use of trail and antiprogestins for treating cancer
EP1362600B1 (de) * 2001-02-20 2008-04-02 AnGes MG, Inc. TOPISCHE ANWENDUNG EINES NF-kB DECOYS ZUR BEHANDLUNG ATOPISCHER DERMATITIS
US20060157072A1 (en) * 2001-06-08 2006-07-20 Anthony Albino Method of reducing the harmful effects of orally or transdermally delivered nicotine
MXPA03011385A (es) * 2001-06-08 2005-03-07 Vector Tobacco Ltd Modeificacion de los niveles de nicotina y nitrosamina en el tabaco.
CA2467915A1 (en) * 2001-11-22 2003-05-30 Anges Mg, Inc. Compositions inhibiting rejection in organ transplantation and method of using the same
DE60231063D1 (de) * 2002-02-01 2009-03-19 Anges Mg Inc N zur behandlung von aneurysmen
WO2003082331A1 (fr) * 2002-03-29 2003-10-09 Anges Mg, Inc. Compositions de leurre destinees au traitement et a la prevention de maladies et de pathologies cerebrales
WO2003086076A1 (en) * 2002-04-09 2003-10-23 Vector Tobacco Ltd. Tobacco having reduced nicotine and nitrosamines
CA2483505A1 (en) 2002-04-26 2003-11-06 Anges Mg, Inc. Circular dumbbell decoy oligodeoxynucleotides (cdodn) containing dna bindings sites of transcription
CN1306964C (zh) * 2002-05-29 2007-03-28 安琪士摩奇株式会社 治疗和预防炎症性疾病的诱饵组合物
EP1541139A4 (de) * 2002-06-26 2008-06-11 Signal Creation Inc Arzneimittelzusammensetzung mit nf-kappa-b-hemmer
JPWO2004026342A1 (ja) * 2002-09-20 2006-01-12 アンジェスＭｇ株式会社 ＮＦκＢデコイを含有する移植片新生内膜肥厚に対する保護剤
EP1647292A4 (de) * 2003-05-09 2011-02-23 Ryuichi Morishita Nadellose spritze mit darin aufgenommenem medizinischen mittel
WO2005004913A1 (ja) * 2003-07-09 2005-01-20 Anges Mg, Inc. デコイを含む薬学的組成物およびその使用方法
US6884443B2 (en) 2003-08-07 2005-04-26 General Mills, Inc. Compositions and methods relating to freezer-to-oven doughs
US7378509B2 (en) 2003-12-02 2008-05-27 Anesiva, Inc. NF-kappaB oligonucleotide decoy molecules
US8372966B2 (en) 2003-12-19 2013-02-12 University Of Cincinnati Oligonucleotide decoys and methods of use
SE0400399D0 (sv) * 2004-02-20 2004-02-20 Index Pharmaceuticals Ab Methods and compositions for the treatment or prevention of secondary ischemic injury
US7482158B2 (en) * 2004-07-01 2009-01-27 Mathison Brian H Composite polynucleic acid therapeutics
AU2005286640A1 (en) * 2004-09-21 2006-03-30 Anesiva, Inc. Delivery of polynucleotides
WO2006043722A1 (ja) * 2004-10-22 2006-04-27 Anges Mg, Inc. キメラ（ダブル）デコイ
EP1839664A4 (de) * 2004-12-16 2009-12-23 Anges Mg Inc Mittel zur regulierung der knochenbildung
US7585848B2 (en) 2005-01-11 2009-09-08 Rush University Medical Center Methods and compositions for treating, inhibiting and reversing disorders of the intervertebral disc
US20090215868A1 (en) * 2005-01-13 2009-08-27 Anges Mg, Inc. Therapeutic Medicament for Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, and Pulmonary Hypertension
US20090214630A1 (en) * 2005-05-10 2009-08-27 Warren Strober Compositions and Methods for the Treatment of Inflammatory Bowel Disease Utilizing NF-KappaB Decoy Polynucleotides
US20060258604A1 (en) * 2005-05-10 2006-11-16 Warren Strober Compositions and methods for the treatment of inflammatory bowel disease utilizing NF-kappaB decoy polynucleotides
JPWO2006132204A1 (ja) * 2005-06-06 2009-01-08 アンジェスＭｇ株式会社 転写因子デコイ
US20100167390A1 (en) * 2005-12-22 2010-07-01 Toshohiro Nakajima Novel Oligonucleotide and NF-kB Decoy Comprising the Same
US8501478B2 (en) * 2006-06-15 2013-08-06 University Of Cincinnati Trehalose click polymers for delivery of biologically active molecules
JP4602298B2 (ja) * 2006-08-31 2010-12-22 ホソカワミクロン株式会社 医薬製剤
EP2127681A4 (de) * 2007-02-16 2011-10-12 Anges Mg Inc Therapeutisches mittel gegen parodontalerkrankungen und alveolar-knochenverlust durch operation
JP5312747B2 (ja) * 2007-03-01 2013-10-09 ジェノミディア株式会社 Ｈｖｊエンベロープによるタンパク質の導入方法
ES2542511T3 (es) * 2007-05-11 2015-08-06 Adynxx, Inc. Expresión génica y dolor
EP2266626B1 (de) * 2008-03-28 2014-06-18 AnGesMG, Inc. Zusammensetzung zur topischen anwendung mit einem transkriptionsfaktor-decoy als wirkstoff
JP5057587B2 (ja) * 2009-05-20 2012-10-24 アンジェスＭｇ株式会社 デコイを含む薬学的組成物およびその使用方法
JPWO2013024763A1 (ja) 2011-08-12 2015-03-05 独立行政法人理化学研究所 核酸アプタマーの作製方法
WO2013170086A2 (en) 2012-05-10 2013-11-14 Adynxx, Inc. Formulations for the delivery of active ingredients
AU2015301491A1 (en) 2014-08-15 2017-02-02 Adynxx, Inc. Oligonucleotide decoys for the treatment of pain
EP3366773A4 (de) * 2015-10-23 2019-06-12 Rena Therapeutics Inc. Nukleinsäurekomplex

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410516B1 (en) * 1986-01-09 2002-06-25 President & Fellows Of Harvard College Nuclear factors associated with transcriptional regulation
CA2102704A1 (en) 1991-05-17 1992-11-18 John Stephen Haskill Inhibitor of nf-kb transcriptional activator and uses thereof
CA2105595A1 (en) * 1992-09-23 1994-03-24 Ramaswamy Narayanan Antisense polynucleotides
CA2131587A1 (en) 1993-09-07 1995-03-08 Yinon Ben-Neriah Method for regulation of nf-kb
EP0652290A1 (de) * 1993-09-07 1995-05-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methode zur Regulierung von NF-kappa B
JPH07114990A (ja) 1993-10-14 1995-05-02 Plus Kk ハロゲンランプ調光装置
PT732929E (pt) * 1993-10-29 2008-08-26 Brigham & Womens Hospital Utilização terapêutica de ''engodos'' de elementos cis in vivo
US6399376B1 (en) * 1993-11-05 2002-06-04 Isis Pharmaceuticals, Inc. Modulation of vascular cell adhesive molecule expression through oligonucleotide interactions
JPH07285504A (ja) 1994-04-14 1995-10-31 Asano Seiki Kk 粉粒体充填装置
DE69636997T2 (de) 1995-05-12 2007-07-12 Anges MG Inc., Ibaraki HEILUNG UND VORBEUGUNG VON DURCH NF-kappaB VERURSACHTEN ERKRANKUNGEN

Also Published As

Publication number Publication date
ES2285712T3 (es) 2007-11-16
US7871983B2 (en) 2011-01-18
DE69636997T2 (de) 2007-07-12
JP3474879B2 (ja) 2003-12-08
US20020098162A1 (en) 2002-07-25
DE69636997D1 (de) 2007-05-10
US20040162250A1 (en) 2004-08-19
WO1996035430A1 (fr) 1996-11-14
EP0824918B1 (de) 2007-03-28
EP0824918A1 (de) 1998-02-25
US6262033B1 (en) 2001-07-17
PT824918E (pt) 2007-06-22
US20060116344A1 (en) 2006-06-01
DK0824918T3 (da) 2007-06-04
EP0824918A4 (de) 2004-11-17

Similar Documents

Publication Publication Date Title
ATE357922T1 (de) Heilung und vorbeugung von durch nf-kappab verursachten erkrankungen
DE122009000012I1 (de) Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzundungen.
DE69318835D1 (de) Behandlung einer refluxstörung durch injektion von mikropartikeln
DE69615510D1 (de) Passivierung von organischen Vorrichtungen
DE69630162D1 (de) Passivierung von organischen Vorrichtungen
DE69319270D1 (de) Verfahren zur Behandlung von organischen Schlämmen
DE69319551D1 (de) Indolin Verbindungen zur Behandlung von Dysurien
DE69613945D1 (de) Passivierung von organischen elektrolumineszenten Vorrichtungen
DE69427869D1 (de) Botulinumtoxine zur behandlung von hyperhydrosis
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
DE69739583D1 (de) Topische zusammensetzungen enthaltend als therapeutisch aktiven wirkstoff ein monoglycerid zur behandlung von schleimhautinfektionen
DE69612003D1 (de) Substituierte benzolaktamverbindungen als substanz-p-antagonisten
FI932695A0 (fi) Angiotensin I kymas-inhibitorer inklusive humant hjaertkymas
ATE301617T1 (de) Behandlung von wasser
DE69331265D1 (de) Verbindungen zur behandlung von entzündlichen erkrankungen und zur hemmung der produktion von tumornekrosefaktor
ATE235481T1 (de) Substituierte benzopyranderivate zur behandlung von entzündungen
DE69603089D1 (de) Zusammensetzung zur behandlung von mauerwerk
DE59309899D1 (de) Stabilisierung von organischen Pigmenten
MX9302932A (es) Nuevas 4-aza-5&-androstan-3-onas 7b-substituidas como inhibidores de la5&-reductasa.
DK0705100T3 (da) Terapeutiske substituerede guanidiner
DE69325673D1 (de) Feldeffekttransistor
ATE161143T1 (de) Neue verwendung von hexaflumuron und verwandte verbindungen als termitizide
DE59307847D1 (de) Stabilisierung von organischen Pigmenten
DE69316203D1 (de) Elektrochemische behandlung von oberflächen
DE69308679D1 (de) Entfernung von flüchtigen organischen Verbindungen aus Polymer-Lösungen und Dispersionen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0824918

Country of ref document: EP